EPHA2 and gastric adenocarcinoma: In 2018, two independent papers determined EPHA2 as the EBV entry receptor in a variety of cancer cell lines including the gastric adenocarcinoma epithelial cell line AGS [12] and the nasopharyngeal carcinoma cell lines CNE1, CNE2 and HNE1 [13].